U.S. Department of Commerce INFORMATION DISCLOSURE STATEMENT				Attorney Docket No. 9409/2045B			Serial No.				
							10/603,566				
J.u/n				Applicant(s):. Wittame	r, et al.						
			.,	Filing Date: June 25, 2003			Group: Not Yet Assigned 164 6				
U.S. PATI	ENT DO	CUMENTS				, 	r				
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)				
FOREIGN	PATE	NT DOCUMENTS									
Examiner		Document No.	Publication	Country	Class	Subclass	Translation				
Initial			Date		<u> </u>		YES	NO			
					<u> </u>	<u> </u>					
				<u> </u>			<u> </u>				
OTHER D	OCUM	ENTS (including Auth	or, Title, Date, Perti	nent Pages, etc.)							
RLi	1.	Adams, et al., "1,25 Dihydroxyvitamin D3 and Dexamethasone Induce the Cyclooxygenase 1 Gene in Osteoclast-Supporting Stromal Cells", (1999), J. of Cellular Biochemistry, 74: 587-595.									
	2.	Nagpal, et al., "Tazarotene-induced Gene 2 (TIG2), a Novel Retinoid-Responsive Gene in Skin", (1997), J. Invest. Dermatol., 109: 91-95.									
	3.	Samson, et al., "ChemR23, a putative chemoattractant receptor, is expressed in monocyte-deriv dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains", Eur. J. Immunology, 28: 1689-1700.									
	4.	Methner, et al., "A Novel G Protein-Coupled Receptor with Homology to Neuropeptide and Chemoattractant Receptors Expressed during Bone Development", (1997), Biochemical and Biophysical Research Communications, 233: 336-342.									
	5										
	6		oost, P., and A. Methner, "Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool or the prediction of orphan receptor ligands", (2002), Genome Biology 3, 0063.1-0063.16.								
,	7	Lee, D.K., S.R. George, J.F. Evans, K.R. Lynch, and B.F. O'Dowd, "Orphan G protein-coupled receptors in the CNS", (2001), Curr. Opin. Pharacol. 1:31-39.									
RL;	8	Im, D.S., "Orphan G	protein-coupled rec	eptors and beyond", (2	.002), <i>Jpi</i>	ı. J. Pharn	nacol. 90:10	1-106.			
EXAMINER Ruisiang L.				DATE	ATE CONSIDERED						
next communica	tion to Appli	rence considered, whether or not citatic cant.	on is in conformance with MPEP 6	609. Draw line through citation if not	in conformance	and not considere	d. Include copy of th	is form with			

USPTO Form Patent and Trademan				Attorney Docket No.		Serial No.			
SUPPLEMENTAL INFORMATION DISCLOSURE				9409/2045B		10/603,66 10/603,566			
STATEMENT									
				Applicant(s):. Communi, et al.					
				Filing Date: June 25, 2004 Group: 1646					
U.S. PAT	ENT DO	CUMENTS	1	T	<u> </u>				
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)		
								<u>-</u>	
FOREIGN PATENT DOCUMENTS									
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation		
minai	:		Date				YES	NO	
		WO/00/31258	2000-June 2	PCT					
		•							
OTHER I	DOCUM	ENTS (including Auth	nor, Title, Date, Pertir	nent Pages, etc.)					
RLi		Communi D. et al "Receptors responsive to extracellular pyrimidine nucleotides" Trends in Pharmocological Sciences, 18(3):83-86 (March 1, 1997)							
		Communi D. et al "Cloning of a Human purinergic P2Y receptor coupled to phospholipase C and adenyl cyclase" Journal of Biological Chemistry 272(51):31969-31973 (December 19, 1997)							
		Owmen et al., Molecular cloning and tissue distribution of a novel chemo-attractant-like receptor, Biochem Biophys Res. Commun. 1997, Dec 18:241(2):390-4							
RLi		Samson et al., ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains, Eur. J. Immunol. 1998 May; 28(5): 1689-700							
	`								
EXAMINER Ruiding L					DATE CO	ONSIDERED 1/6 /2→ 6			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.									
**Copies of refe	erences not pro	vided at the time of this submission.							